How to Localize Labels and Instructions for Overseas Registration of IVD Products?

For overseas registration of in-vitro diagnostic (IVD) products, localizing labels and instructions for use is a key compliance step. Manufacturers must first determine whether the product falls within the medical device regulatory scope of the target country, then identify the registration pathway based on risk class. For GHWP member states, Southeast Asia, the Middle East, Latin America, and similar markets, core technical files may be reusable, but labels and instructions must be fully localized, including language translation, unit conversion, symbol adjustments, and adaptation to local regulatory requirements (e.g., EU IVDR, US FDA, China NMPA, Japan PMDA).

Key Points

Common risks include misleading language due to inaccurate translation, omission of required warnings, non-compliance with local registration document formats, and failure to account for local representative responsibilities. Manufacturers should prepare technical documentation, performance validation, risk management, and clinical evaluation evidence, and ensure continued compliance with post-market maintenance obligations. During localization, close collaboration with local agents or authorized representatives is essential to ensure smooth change control and certificate renewal. For multi-country registration, using a unified core document set while localizing per market reduces the risk of duplicate efforts and deficiency corrections.

For Chinese medical device manufacturers, a practical approach is to first perform product classification and document gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Target market registration usually affects technical files, authorized representatives, importer coordination, label language, quality system evidence, and subsequent change maintenance. If the project is managed simply as a “which documents to submit” exercise, deficiencies or rework may arise in model coverage, consistency of evidence chains, label claims, and certificate control.

AIMEILI recommends that manufacturers address this issue within an overall GHWP member-state and multi-country market access strategy, supporting localization with a single reusable core technical file rather than recreating documentation for each country.

Applicable Scenarios and Core Questions

When registering IVD products overseas, labels and instructions must meet target country regulatory requirements. Localization is not merely language translation; it also involves converting measurement units, symbols, warnings, indications, intended use descriptions, storage conditions, and other elements. Different countries and regions have specific requirements for label content, format, language, and symbols. For example, the EU IVDR requires labels in official languages; the US FDA requires English and compliance with 21 CFR 801/809; China requires Chinese and compliance with the “Provisions for the Administration of Medical Device Labels and Instructions.” When formulating a localization strategy, manufacturers should first confirm the target countries, determine whether they are GHWP member states, and assess whether they recognize registration data from other markets.

Core questions include: Is the product within the scope of medical device regulation? What is the risk class? Is the registration pathway self-declaration or review by a notified body? Which existing NMPA, CE, FDA, ISO 13485, or MDSAP documents can be reused? What content in labels and instructions must be adjusted? What are the responsibilities of the local agent or authorized representative? How do you maintain label and instruction changes after market entry?

Registration Determination Logic

Step 1: Confirm the target country regulatory authority and scope

For example, the EU IVDR applies to in vitro diagnostic medical devices; the US FDA regulates IVDs as medical devices; China's NMPA classifies IVDs into Class I, II, or III based on risk.

Step 2: Determine the registration pathway by product classification

High-risk IVDs generally require technical documentation review, clinical evaluation, and quality management system audits. Low-risk products may only need to meet basic requirements and undergo self-declaration.

Step 3: Assess reusability of existing documents

CE or FDA approved technical documentation, performance verification data, risk management reports, and clinical evidence can serve as a foundation, but gap analysis must be performed to identify local differences.

Step 4: Complete full localization of labels and instructions

This includes language translation, format adjustment, symbol replacement, addition of warnings, and alignment of intended use descriptions with local clinical practice.

Step 5: Identify the local agent or authorized representative

The representative is responsible for communication with regulatory authorities and post-market surveillance.

Step 6: Plan post-market maintenance

This includes change notification, certificate renewal, and adverse event reporting.

Documentation and Evidence for Localization

Manufacturers should prepare the following when localizing labels and instructions:

• Original registration technical files (including product description, intended use, performance specifications, risk management report, and clinical evidence)
• Original label and instruction design files
• Translated versions and proofreading records
• Localization compliance declaration (stating conformity with local regulatory requirements)
• Cooperation agreement with the local agent

For multi-country registration, establish a core label and instruction template and adjust per country based on specific differences. The evidence chain should include translation qualification certificates (e.g., professional medical translation organization credentials), language confirmation documents, regulatory compliance checklists, and change control records. Retain original design documents to prove consistency between the localized versions and the original during regulatory review.

Common Mistakes in Localization

• Directly translating CE or FDA labels and instructions without considering local regulatory differences, such as omitting required local warnings or contraindications.
• Failing to convert measurement units, e.g., keeping imperial or non-compliant units, which may cause use errors.
• Improper symbol usage. For example, the CE mark and notified body number are required in the EU, but other markets may not recognize them or may require additional markings.
• Intended use descriptions that are inconsistent with local clinical practice, leading to registration rejection.
• Overlooking the local representative responsibility by not showing authorized representative or importer information on labels.
• Inadequate change control, releasing updated versions without re-evaluation.
• Inaccurate language translation or incorrect technical terminology, which may lead to serious misunderstanding.

Manufacturer Preparation Checklist

• Confirm target country regulatory requirements, especially for label and instruction language, content, format, and symbols.
• Establish a core label and instruction template containing all essential elements (intended use, storage conditions, expiry date, warnings, contraindications, manufacturer information, authorized representative, etc.).
• Commission professional medical translators for localization and arrange peer review.
• Prepare a localization compliance declaration with translation certificates and a regulation comparison table.
• Sign agreements with local agents and define responsibilities.
• Set up a post-market change control process to ensure every update is notified to the agent and filed.
• Maintain records of all versions for regulatory inspection.

AIMEILI Regulatory Interpretation and Business Impact

Regulatory Interpretation

The most common misjudgment is believing that once CE or FDA approval is obtained, other markets can directly accept the same documents. In reality, label and instruction localization requires deep understanding of local culture, language habits, and medical practice. A regulatory gap analysis at the project planning stage is critical to identify which content must be revised. Core technical files such as performance validation and risk management can be reused, but labels and instructions must be fully localized. The selection of the local agent or authorized representative directly affects certificate control; all changes and renewals must go through that representative, or registration may lapse.

Business Impact

For multi-country registration, using a core document set with localized appendices significantly reduces the risk of duplicate document preparation and deficiencies. Manufacturers should allocate sufficient time for localization review and registration approval to avoid delays. In actual project execution, treat this task as five sub-tasks: regulatory judgment, document preparation, evidence reuse, localization transfer, and post-market maintenance. This approach surfaces documentation gaps earlier and ensures sales, R&D, quality, and regulatory teams share a consistent understanding of target country requirements.

Quality System and Consistency of Evidence

From a regulatory review perspective, quality system documentation is not an isolated certificate. Regulators check consistency among manufacturer name, production address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 certificate scope does not match the submitted product, or if the production address, model numbers, or instruction versions are inconsistent with test reports, even extensive documentation may trigger requests for clarification. Establish a consistency checklist before submission, mapping product name, model, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management versions, label versions, and quality system certificates side by side. This basic step can significantly reduce deficiency notifications, particularly for projects in multiple GHWP member states or multiple product lines submitted simultaneously.

Localization Transfer and Agent Responsibility

Target market registration projects typically involve local agents, authorized representatives, importers, or registration holders. Manufacturers must confirm early whether the local partner is only responsible for submitting documentation or also handles regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability. Labels and instructions cannot be simple translated. Verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For manufacturers with CE, FDA, NMPA, or other market approvals, localization transfer should focus on converting reusable evidence into a submission structure acceptable to the target country, not on writing entirely separate documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance. Manufacturers must maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label version control, and regulatory update records. Many manufacturers invest significant effort in obtaining certificates but neglect post-market maintenance. Later changes such as production address changes, model extensions, instruction updates, or agent replacements may cause the certificate to become disconnected from market sales. AIMEILI recommends integrating this issue into the annual international registration plan: first prioritize target markets, then build reusable document packages and country-specific gap lists, and finally schedule submission, deficiency responses, post-market maintenance, and renewal milestones. This approach not only improves registration efficiency in individual countries but also builds a replicable compliance capability for going global, reducing the cost of starting from scratch each time a new market is entered.

The content is based on the AIMEILI registration practice database, medical device international registration knowledge base, and publicly available regulatory information. Specific projects should follow the target country's regulatory authority requirements and the manufacturer's product documentation.